Enter your search terms:
Top

Press Releases

09.11.2018
Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel

 

09.04.2018
Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™

 

08.31.2018
Aquestive Therapeutics Announces Tentative FDA Approval for Sympazan™ (clobazam) Oral Film

 

08.15.2018
Aquestive Therapeutics Announces Closing of Exercise of Underwriters' Over-Allotment Option in Initial Public Offering

 

08.13.2018
Aquestive Therapeutics Names Sandy Costa as Chairman of the Board of Directors

 

07.31.2018
Aquestive Therapeutics to Present at the 2018 Wedbush Healthcare Conference

 

07.27.2018
Aquestive Therapeutics Announces Closing of Initial Public Offering

 

07.24.2018
Aquestive Therapeutics Announces Pricing of Initial Public Offering

 

07.16.2018
Court Ruling in Favor of Aquestive Therapeutics Enjoining Dr. Reddy's Laboratories from Launching its Generic Suboxone Product

 

05.18.2018
Aquestive Therapeutics Settles Patent Infringement Case with Par Pharmaceuticals

 

05.02.2018
Aquestive Therapeutics Appoints Nancy Lurker to Board of Directors

 

01.31.2018
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Designation for Riluzole Oral Soluble Film to Treat ALS

 

01.18.2018
Aquestive Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Clobazam Oral Soluble Film to Treat Lennox-Gastaut Syndrome

 

11.30.2017
MonoSol Rx Changes Name to Aquestive Therapeutics and Expands CNS Product Portfolio

 

Events

Presentations

Latest comments

Sorry, the comment form is closed at this time.